Merck Not Feeling Mega-Merger Mania Even As Pharma Sales Decline
This article was originally published in The Pink Sheet Daily
Executive Summary
Patent expiries for five products drag down revenue, but biotech deals and pipeline building remain Merck’s strategy, CEO Frazier says.